Literature DB >> 22955353

Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains.

Luca Mogna1, Mario Del Piano, Francesca Deidda, Stefania Nicola, Liliana Soattini, Rosaria Debiaggi, Filomena Sforza, Gianpaolo Strozzi, Giovanni Mogna.   

Abstract

BACKGROUND: Lactobacilli and bifidobacteria are often associated with health-promoting effects. These live microorganisms, defined as probiotics, are commonly consumed as part of fermented foods, such as yoghurt and fermented milks, or as dietary supplements. Escherichia coli is a gram-negative, rod-shaped bacterium commonly found in the lower intestine of warm-blooded organisms. As a part of the normal gut microbiota, this microorganism colonizes the gastrointestinal tract of animals and humans within a few hours after birth. All E. coli strains can produce a wide variety of biogenic amines responsible for potentially harmful systemic intoxications. Enterohemorrhagic E. coli serotype O157:H7 is a pathotype of diarrhoeagenic strains with a large virulence plasmid pO157 able to produce 1 or more Shiga toxins.
METHODS: The overall aim of this study was to determine the inhibitory effects of different strains of probiotics on E. coli serotypes, including E. coli O157:H7 (CQ9485). In particular, the antagonistic activity of 4 Bifidobacterium strains (Probiotical SpA, Italy) and 16 lactic acid bacteria, more specifically 14 Lactobacillus spp. and 2 Streptococcus spp., was assessed against selected E. coli biotypes (ATCC 8739, ATCC 10536, ATCC 35218, and ATCC 25922). The diarrhoeagenic serotype O157:H7 was also tested.
RESULTS: The experimental data collected demonstrated an in vitro significant inhibitory effect of 6 Lactobacillus strains, namely L. rhamnosus LR04, L. rhamnosus LR06, L. plantarum LP01, L. plantarum LP02, L. pentosus LPS01, and L. delbrueckii subsp. delbrueckii LDD01, and 2 Bifidobacterium strains, B. breve BR03 and B. breve B632. The inhibiting extent was slightly different among these strains, with L. delbrueckii subsp. delbrueckii LDD01 showing the highest activity on E. coli O157:H7.
CONCLUSIONS: Most of the probiotics studied are able to antagonize the growth of the 5 strains of E. coli tested, including the O157:H7 biotype, well known for their characteristic to produce a wide variety of biogenic amines considered responsible for dangerous systemic intoxications.

Entities:  

Mesh:

Year:  2012        PMID: 22955353     DOI: 10.1097/MCG.0b013e31826852b7

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  13 in total

Review 1.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 2.  Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer.

Authors:  Luigi Marongiu; Markus Burkard; Sascha Venturelli; Heike Allgayer
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

Review 3.  Probiotics and the Treatment of Parkinson's Disease: An Update.

Authors:  Hamed Mirzaei; Saman Sedighi; Ebrahim Kouchaki; Erfaneh Barati; Ehsan Dadgostar; Michael Aschner; Omid Reza Tamtaji
Journal:  Cell Mol Neurobiol       Date:  2021-07-20       Impact factor: 4.231

Review 4.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 5.  Therapeutic Microbiology: The Role of Bifidobacterium breve as Food Supplement for the Prevention/Treatment of Paediatric Diseases.

Authors:  Nicole Bozzi Cionci; Loredana Baffoni; Francesca Gaggìa; Diana Di Gioia
Journal:  Nutrients       Date:  2018-11-10       Impact factor: 5.717

6.  Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence.

Authors:  Luca Magistrelli; Angela Amoruso; Luca Mogna; Teresa Graziano; Roberto Cantello; Marco Pane; Cristoforo Comi
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

Review 7.  Management of STEC Gastroenteritis: Is There a Role for Probiotics?

Authors:  Mario Giordano; Maria Elisabetta Baldassarre; Viviana Palmieri; Diletta D Torres; Vincenza Carbone; Luisa Santangelo; Federico Gentile; Raffaella Panza; Federica Di Mauro; Manuela Capozza; Antonio Di Mauro; Nicola Laforgia
Journal:  Int J Environ Res Public Health       Date:  2019-05-12       Impact factor: 3.390

8.  The Biotherapeutic Potential of Lactobacillus reuteri Characterized Using a Target-Specific Selection Process.

Authors:  Valeria Sagheddu; Francesca Uggeri; Luisella Belogi; Laura Remollino; Paola Brun; Giulia Bernabè; Giancarlo Moretti; Andrea Porzionato; Lorenzo Morelli; Ignazio Castagliuolo; Marina Elli
Journal:  Front Microbiol       Date:  2020-04-15       Impact factor: 5.640

9.  The Early Intestinal Microbiota of Healthy Korean Newborns.

Authors:  Eu Kyoung Lee; Young Tae Ahn; Chul Sung Huh; Hwan Soo Kim; Eugene Kim; Yoon Hong Chun; Jong-Seo Yoon; Hyun Hee Kim; Jin Tack Kim
Journal:  Iran J Pediatr       Date:  2015-10-06       Impact factor: 0.364

Review 10.  Review of the inhibition of biological activities of food-related selected toxins by natural compounds.

Authors:  Mendel Friedman; Reuven Rasooly
Journal:  Toxins (Basel)       Date:  2013-04-23       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.